Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults	brain disorder, central nervous system disorder, headache disorder, hypnic headache, migraine disorder, nervous system disorder	Not yet recruiting	Phase 3	2026-09-25		NCT07835152

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Brise Pharmaceuticals Co., Ltd.	2

81 results · Page 1 of 4

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Affiliated Hospital of Jining Medical University	Shandong	China	2
Baoji Central Hospital	Shanxi	China	2
Beijing Friendship Hospital, Capital Medical University	Beijing	China	64
Cangzhou Central Hospital	Hebei	China	2
Changsha Central Hospital	Hunan	China	2
Chonggang General Hospital	Chongqing	China	2
Chongqing University Three Gorges Hospital	Chongqing	China	8
Dalian Municipal Central Hospital, Affiliated to Dalian University of Technology	Liaoning	China	2
Dazhou Central Hospital	Sichuan	China	2
First Medical Center of Chinese PLA General Hospital	Beijing	China	3
General Hospital of Northern Theater Command of Chinese PLA	Liaoning	China	2
Guangdong Provincial People's Hospital	Guangdong	China	1
Guangzhou First People's Hospital	Guangdong	China	2
Hebei General Hospital	Hebei	China	2
Huanggang Central Hospital	Hubei	China	2
Huashan Hospital, Fudan University	Shanghai	China	40
Huzhou Central Hospital	Zhengjiang	China	1
Inner Mongolia Autonomous Region People's Hospital	Inner Mongolia	China	2
Jinan Central Hospital	Shandong	China	2
Jingzhou First People's Hospital	Hubei	China	2
Liaocheng People's Hospital	Shandong	China	2
Nanjing Brain Hospital	Jiangsu	China	2
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences	Beijing	China	11
Peking University People's Hospital	Beijing	China	146
Peking University Third Hospital	Beijing	China	123

Clinical trials